To gain a more profound insight into this question in a clinically relevant context, we aim to collect tumor samples from CML patients, and explore potential correlations between cellular neddylation levels and therapeutic outcomes of BCR::ABL1-targeting TKIs. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.